This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hebbar, M. Articles by Peyrat, J.-P. Search for Related Content PubMed PubMed Citation Articles by Hebbar, M. Articles by Peyrat, J.-P.

Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients¹

Laboratoire d’Oncologie Moléculaire Humaine [M. H., F. R., M-M. L., J-P. P.], Département d’Informatique Médicale [C. F.], and Département d’Oncologie Médicale [M. H., J. B.], Centre Oscar Lambret, 59020 Lille Cedex, France

Several studies have suggested that endothelial cells participate in tumor development. Soluble E-selectin (sE-selectin) is specifically released by activated endothelial cells, and its serum concentration can be considered a marker of endothelial activation. In this study, we assessed the prognostic value of sE-selectin concentrations in node-negative breast cancer patients. Serum sE-selectin concentrations were measured by an ELISA method prior to surgery in 456 node-negative breast cancer patients. We analyzed also tumor size (TS), histoprognostic grading, and steroid hormone receptor status. The mean sE-selectin concentration was 24.9 ± 15.0 ng/ml. The sE-selectin concentrations were mildly correlated with the TS but not with the other factors. For prognostic analyses, the median follow-up duration was 7.5 years. The cutoff sE-selectin concentration used was 40 ng/ml. In overall survival studies, univariate analyses demonstrated a prognostic value of sE-selectin, TS, and histoprognostic grading, and multivariate analyses demonstrated a prognostic value of sE-selectin and TS. For disease-free survival, univariate and multivariate analyses demonstrated a prognostic value of sE-selectin and TS. sE-selectin concentration is an easily measurable and strong prognostic factor in node-negative breast cancer patients. These results provide further evidence for the role of adhesion molecules expression by endothelial cells in tumor progression.

This article has been cited by other articles:

				B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al. Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients. Clin. Cancer Res., May 15, 2006; 12(10): 3124 - 3129. [Abstract] [Full Text] [PDF]

				J. Laferriere, F. Houle, M. M. Taher, K. Valerie, and J. Huot Transendothelial Migration of Colon Carcinoma Cells Requires Expression of E-selectin by Endothelial Cells and Activation of Stress-activated Protein Kinase-2 (SAPK2/p38) in the Tumor Cells J. Biol. Chem., August 31, 2001; 276(36): 33762 - 33772. [Abstract] [Full Text] [PDF]